JP2014533938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533938A5 JP2014533938A5 JP2014537355A JP2014537355A JP2014533938A5 JP 2014533938 A5 JP2014533938 A5 JP 2014533938A5 JP 2014537355 A JP2014537355 A JP 2014537355A JP 2014537355 A JP2014537355 A JP 2014537355A JP 2014533938 A5 JP2014533938 A5 JP 2014533938A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- cell
- vaccine
- cells
- apoptotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 8
- 210000004443 dendritic cell Anatomy 0.000 claims 7
- 102100037850 Interferon gamma Human genes 0.000 claims 6
- 108010074328 Interferon-gamma Proteins 0.000 claims 6
- 230000002886 autophagic effect Effects 0.000 claims 5
- 230000004987 nonapoptotic effect Effects 0.000 claims 5
- 230000004083 survival effect Effects 0.000 claims 5
- 230000005867 T cell response Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 229940115256 melanoma vaccine Drugs 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 229940030325 tumor cell vaccine Drugs 0.000 claims 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 claims 1
- 102000000412 Annexin Human genes 0.000 claims 1
- 108050008874 Annexin Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 claims 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 238000013096 assay test Methods 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549681P | 2011-10-20 | 2011-10-20 | |
| US61/549,681 | 2011-10-20 | ||
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| US61/594,304 | 2012-02-02 | ||
| PCT/US2012/061294 WO2013059778A2 (en) | 2011-10-20 | 2012-10-22 | Antigen presenting cancer vaccine with gamma interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014533938A JP2014533938A (ja) | 2014-12-18 |
| JP2014533938A5 true JP2014533938A5 (enExample) | 2016-02-25 |
Family
ID=48141460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537358A Pending JP2014530627A (ja) | 2011-10-20 | 2012-10-22 | 抗原提示癌ワクチン |
| JP2014537355A Pending JP2014533938A (ja) | 2011-10-20 | 2012-10-22 | γインターフェロンを用いた抗原提示癌ワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537358A Pending JP2014530627A (ja) | 2011-10-20 | 2012-10-22 | 抗原提示癌ワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9555058B2 (enExample) |
| EP (2) | EP2768519A4 (enExample) |
| JP (2) | JP2014530627A (enExample) |
| KR (2) | KR20150016200A (enExample) |
| CN (5) | CN105288602A (enExample) |
| AU (2) | AU2012325764A1 (enExample) |
| CA (2) | CA2852960A1 (enExample) |
| HK (2) | HK1201176A1 (enExample) |
| IL (2) | IL232173A0 (enExample) |
| SG (4) | SG11201401631VA (enExample) |
| WO (2) | WO2013059784A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865830B1 (fr) | 2004-01-30 | 2006-05-19 | Neopost Ind | Systeme d'affranchissement de courrier a mode d'impression externe securise |
| CN105288602A (zh) | 2011-10-20 | 2016-02-03 | 新干细胞肿瘤学有限责任公司 | 具有γ干扰素的抗原呈递癌症疫苗 |
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| JP6967963B2 (ja) * | 2014-07-17 | 2021-11-17 | ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. | 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法 |
| KR20180126085A (ko) * | 2016-05-05 | 2018-11-26 | 난토믹스, 엘엘씨 | 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor) |
| CA3053939A1 (en) * | 2017-02-17 | 2018-08-23 | Aivita Biomedical, Inc. | Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells |
| WO2024107624A1 (en) * | 2022-11-14 | 2024-05-23 | Shattuck Labs, Inc. | Methods of overcoming resistance to checkpoint inhibitor therapies |
| CN118441033B (zh) * | 2024-04-24 | 2025-06-20 | 广西医科大学 | HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0598998B1 (en) * | 1992-09-07 | 2004-05-19 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies reacting with the ganglioside GM2 |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| CA2321093A1 (en) | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| AU8026800A (en) | 1999-10-15 | 2001-04-30 | Baylor Research Institute | Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| US7015205B1 (en) * | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| DK1448229T3 (da) * | 2001-11-29 | 2010-03-08 | Dandrit Biotech As | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr |
| GB0130720D0 (en) * | 2001-12-21 | 2002-02-06 | Serono Internat S A | Proteins |
| CN1443778A (zh) * | 2002-03-13 | 2003-09-24 | 上海中信国健药业有限公司 | 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物 |
| US20060140983A1 (en) * | 2004-10-25 | 2006-06-29 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| WO2007016340A2 (en) * | 2005-07-29 | 2007-02-08 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| EP1951318B1 (en) * | 2005-11-07 | 2012-10-17 | British Columbia Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| EP2630968A1 (en) * | 2006-06-30 | 2013-08-28 | Baylor Research Institute | Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells |
| AR060424A1 (es) | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
| CN105288602A (zh) | 2011-10-20 | 2016-02-03 | 新干细胞肿瘤学有限责任公司 | 具有γ干扰素的抗原呈递癌症疫苗 |
-
2012
- 2012-10-22 CN CN201510706438.6A patent/CN105288602A/zh active Pending
- 2012-10-22 JP JP2014537358A patent/JP2014530627A/ja active Pending
- 2012-10-22 HK HK15101637.0A patent/HK1201176A1/xx unknown
- 2012-10-22 US US14/352,983 patent/US9555058B2/en not_active Expired - Fee Related
- 2012-10-22 SG SG11201401631VA patent/SG11201401631VA/en unknown
- 2012-10-22 SG SG10201602424RA patent/SG10201602424RA/en unknown
- 2012-10-22 KR KR1020147013353A patent/KR20150016200A/ko not_active Withdrawn
- 2012-10-22 WO PCT/US2012/061306 patent/WO2013059784A1/en not_active Ceased
- 2012-10-22 AU AU2012325764A patent/AU2012325764A1/en not_active Abandoned
- 2012-10-22 AU AU2012325758A patent/AU2012325758A1/en not_active Abandoned
- 2012-10-22 CA CA2852960A patent/CA2852960A1/en not_active Abandoned
- 2012-10-22 EP EP12841839.9A patent/EP2768519A4/en not_active Withdrawn
- 2012-10-22 CN CN201610218244.6A patent/CN105861437A/zh not_active Withdrawn
- 2012-10-22 EP EP12842230.0A patent/EP2768534A4/en not_active Withdrawn
- 2012-10-22 WO PCT/US2012/061294 patent/WO2013059778A2/en not_active Ceased
- 2012-10-22 US US14/352,982 patent/US20140308316A1/en not_active Abandoned
- 2012-10-22 CN CN201610301904.7A patent/CN105999249A/zh active Pending
- 2012-10-22 HK HK15101635.2A patent/HK1201175A1/xx unknown
- 2012-10-22 SG SG11201401632WA patent/SG11201401632WA/en unknown
- 2012-10-22 CN CN201280051799.6A patent/CN103917246A/zh active Pending
- 2012-10-22 CA CA2852967A patent/CA2852967A1/en not_active Abandoned
- 2012-10-22 JP JP2014537355A patent/JP2014533938A/ja active Pending
- 2012-10-22 SG SG10201508535RA patent/SG10201508535RA/en unknown
- 2012-10-22 KR KR1020147013355A patent/KR20150004791A/ko not_active Withdrawn
- 2012-10-22 CN CN201280051821.7A patent/CN103957925A/zh active Pending
-
2014
- 2014-04-22 IL IL232173A patent/IL232173A0/en unknown
- 2014-04-22 IL IL232172A patent/IL232172A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530627A5 (enExample) | ||
| Kumai et al. | Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses | |
| Hailemichael et al. | Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion | |
| EP2696894B1 (en) | Method for priming of t cells | |
| Padte et al. | A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates | |
| JP2010514455A5 (enExample) | ||
| JP2014514927A5 (enExample) | ||
| Hong et al. | Configuration-dependent presentation of multivalent IL-15: IL-15Rα enhances the antigen-specific T cell response and anti-tumor immunity | |
| Sin et al. | Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2180–188 peptides | |
| SI2102331T1 (sl) | Antitumorsko cepivo, izvedeno iz normalnih kemično modificiranih CD4+ celic | |
| MX2020011675A (es) | Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal. | |
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| CA2796379A1 (en) | Method for proliferation of antigen-specific t cells | |
| CR20220115A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522) | |
| MX2013012219A (es) | Método de administración de vacunas. | |
| Aspord et al. | pDCs efficiently process synthetic long peptides to induce functional virus‐and tumour‐specific T‐cell responses | |
| CN104379730A (zh) | 使树突细胞成熟的组合物以及用其制备抗原特异性树突细胞的方法 | |
| Shimabukuro-Vornhagen et al. | The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect | |
| MX2023001622A (es) | Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada. | |
| JP2015506698A5 (enExample) | ||
| US9089593B2 (en) | Dendritic cell tumor injection (DCTI) therapy | |
| Yang et al. | HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma | |
| Ota et al. | Vaccination of acute leukemia patients with WT1 peptide-pulsed dendritic cells induces immunological and clinical responses: a pilot study |